CancerTYPE ID test: Pivotal trial data

bioMerieux's bioTheranostics Inc. subsidiary reported data from a pivotal trial in 790 tumor samples showing that the CancerTYPE ID test had 79% and 100% sensitivity and specificity, respectively, for...